Literature DB >> 34423517

Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics.

Nicole K Yun1, Jessica A Slostad2, Ankur Naqib3, Casey Frankenberger3, Claudia B Perez4, Ritu Ghai5, Lydia Usha2.   

Abstract

Next-generation sequencing (NGS) technologies have become increasingly used for managing breast cancer. In addition to the conventional use of NGS for predicting recurrence risk and identifying potential actionable mutations, NGS can also serve as a powerful tool to understand clonal origin and evolution of tumor pairs and play a unique role in clarifying complex clinical presentations. We report an unusual case of early-stage breast cancer in which the primary tumor and draining axillary node were histologically discordant. The primary tumor was invasive lobular carcinoma, whereas the nodal metastasis was invasive ductal carcinoma. This discordance led us to question whether the tumors had the same origin. NGS performed on both specimens identified no overlapping variants, leading us to conclude that the patient had two separate primary breast cancers, with the nodal tumor representing metastasis from an occult breast cancer. DNA sequencing of the primary tumor and the nodal metastasis allowed us to predict the patient's recurrence risk, and we initiated adjuvant chemotherapy and hormonal therapy based on these results. This case illustrates the utility of NGS for successfully managing a rare and challenging case. KEY POINTS: A degree of molecular concordance is expected for tumors originating from a common stem or progenitor cell. Histological discordance and absence of any genomic overlap should raise suspicion for two separate primary tumors. Paired DNA sequencing of the primary tumor and nodal metastasis can inform clinical decisions when primary breast tumor and axillary metastasis are histologically discordant. Molecular/Precision Oncology Tumor Board is the best setting to facilitate such decisions in these challenging cases. Paired DNA sequencing under these rare circumstances may suggest an occult breast tumor.
© 2021 AlphaMed Press.

Entities:  

Keywords:  Breast cancer; Cancer stem cells; Genomic sequencing; Histologic discordance; Next-generation sequencing; Occult breast cancer

Mesh:

Year:  2021        PMID: 34423517      PMCID: PMC8649033          DOI: 10.1002/onco.13952

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  25 in total

1.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

2.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Catherine Van Poznak; Mark R Somerfield; Robert C Bast; Massimo Cristofanilli; Matthew P Goetz; Ana M Gonzalez-Angulo; David G Hicks; Elizabeth G Hill; Minetta C Liu; Wanda Lucas; Ingrid A Mayer; Robert G Mennel; William F Symmans; Daniel F Hayes; Lyndsay N Harris
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

3.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07

4.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 5.  Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review.

Authors:  J de Bresser; B de Vos; F van der Ent; K Hulsewé
Journal:  Eur J Surg Oncol       Date:  2009-10-12       Impact factor: 4.424

6.  Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis.

Authors:  Rachel E Ellsworth; Allyson L Toro; Heather L Blackburn; Alisha Decewicz; Brenda Deyarmin; Kimberly A Mamula; Nicholas S Costantino; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Cancer Growth Metastasis       Date:  2015-07-20

7.  Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Authors:  Hirokazu Matsushita; Matthew D Vesely; Daniel C Koboldt; Charles G Rickert; Ravindra Uppaluri; Vincent J Magrini; Cora D Arthur; J Michael White; Yee-Shiuan Chen; Lauren K Shea; Jasreet Hundal; Michael C Wendl; Ryan Demeter; Todd Wylie; James P Allison; Mark J Smyth; Lloyd J Old; Elaine R Mardis; Robert D Schreiber
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

Review 8.  Tumor Heterogeneity in Breast Cancer.

Authors:  Gulisa Turashvili; Edi Brogi
Journal:  Front Med (Lausanne)       Date:  2017-12-08

9.  Clinicopathological Evaluation of the Potential Anatomic Pathways of Systemic Metastasis from Primary Breast Cancer Suggests an Orderly Spread Through the Regional Lymph Nodes.

Authors:  S David Nathanson; Shravan Leonard-Murali; Charlotte Burmeister; Laura Susick; Patricia Baker
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 10.  Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.

Authors:  Luise Müller; Antje Tunger; Ioana Plesca; Rebekka Wehner; Achim Temme; Dana Westphal; Friedegund Meier; Michael Bachmann; Marc Schmitz
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.